Chronic or recurrent vaginal candidosis: short-term treatment and prophylaxis with itraconazole.
Twenty-one women (mean age, 35.3 years) with 2 to 4 episodes of vaginal candidosis in the last 6 months were included in the study to evaluate the efficacy and safety of itraconazole as short-term, as well as prophylactic, treatment of chronic candidosis. After clinical evaluation and laboratory confirmation of candidosis, 200 mg of itraconazole were given orally for 3 days. Twelve of the 21 patients were cured. The remaining nine repeated treatment, after which all were cured. All patients were entered in the maintenance phase, and received 200 mg of itraconazole the first day of the menstrual cycle for 6 months. One patient relapsed in the second month, but after taking 200 mg of itraconazole BID for 1 day she remained cured for the rest of the study period. All other patients remained cured for the 6 months of the maintenance period. Three months after the end of prophylactic therapy, 17 of 20 patients (85%) were clinically and mycologically cured. No adverse experiences were reported. It is concluded that itraconazole is an efficient and safe short-term treatment for chronic or recurrent vaginal candidosis. Moreover, the dose of 200 mg once monthly for 6 months proved to be a successful suppressive treatment.
Creatsas
G C
GC
First Department of Obstetrics and Gynaecology, University of Athens, Greece.
Charalambidis
V M
VM
Zagotzidou
E H
EH
Anthopoulou
H N
HN
Michailidis
D C
DC
Aravantinos
D I
DI
D000293:Adolescent; D000328:Adult; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000517:prevention & control; D002908:Chronic Disease; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors
D017964:Itraconazole